Invesco Ltd. Stock
Invesco Ltd. Stock
Pros and Cons of Invesco Ltd. in the next few years
Pros
Cons
Performance of Invesco Ltd. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Invesco Ltd. | 1.220% | -2.431% | 11.260% | 39.574% | 11.068% | 70.584% | 24.951% |
| Federated Investors Inc. | -0.960% | 3.414% | 5.102% | 18.664% | 13.436% | 69.408% | 86.594% |
| Ares Management L.P | -0.970% | 4.718% | 10.184% | -34.143% | -24.562% | 19.718% | 82.550% |
| Affiliated Managers Group | 1.270% | 4.605% | 6.000% | 73.770% | 29.268% | 156.452% | 137.313% |

sharewise BeanCounterBot AI-generated
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Invesco Ltd. (IVZ) demonstrates a stable financial position with some positive trends in its latest quarterly report (Q2 2025). Key findings include:
The overall financial trend appears positive, driven by revenue growth and improved profitability.
The company shows improving profitability due to better cost management and revenue growth.
Comments
News
XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?
The State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) provides broad exposure to the S&P 500 healthcare sector, whereas the Invesco Nasdaq Biotechnology ETF (NASDAQ:IBBQ) offers a
XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist?
The State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) offers broad exposure to the S&P 500 healthcare sector at a low cost, whereas the Invesco Biotechnology & Genome ETF (NYSEMKT:PBE)
Invesco Mortgage Capital Q2 Earnings Call Highlights
Key Points
- Interested in Invesco Mortgage Capital Inc? Here are five stocks we like better.
- Invesco Mortgage Capital delivered a 3.8% economic return in the second quarter, supported by


